News | EP Lab | July 28, 2021

St. Jude Medical Pays $27 Million for Allegedly Selling Defective Heart Devices

St. Jude Medical Pays $27 Million for Allegedly Selling Defective ICD and CRT-D devices

July 28, 2021 — The U.S. Justice Department announced earlier this month that St. Jude Medical Inc. agreed to pay $27 million to settle allegations under the False Claims Act involving its implantable cardioverter defibrillators (ICD) and cardiac resyncronization therapy defibrillators (CRT-D). Between November 2014 and October 2016, the Justice Department said St. Jude knowingly sold defective electrophysiology (EP) devices to healthcare facilities that implanted the devices into patients insured by federal healthcare programs.

This issue relates to a matter that took place prior to Abbott’s acquisition of St. Jude Medical in 2017.

The government alleges that St. Jude failed to disclose serious adverse health events in connection with the premature depletion of the battery in certain models of its Fortify, Fortify Assura ICDs, and Quadra and Unify CRT-D devices. The devices are surgically implanted into patients’ chests, and when the devices detect an irregular heartbeat, they send an electrical pulse to the heart to shock it back to its normal rhythm. The government alleged that, by 2013, St. Jude knew that lithium clusters formed on the batteries of the devices, causing some of the batteries to short out and suffer premature power drain. 

“To ensure the health and safety of patients, manufacturers of implantable cardiac devices must be transparent when communicating with the government about safety issues and incidents,” said Acting Assistant Attorney General Brian M. Boynton of the Justice Department’s Civil Division. “We will hold accountable those companies whose conduct violates the law and puts patients’ health at risk.”

“Medical device manufacturers have an obligation to be truthful with the Food and Drug Administration (FDA), and the U.S. government will not pay for devices that are unsafe and risk injury or death,” said Acting U.S. Attorney Jonathan F. Lenzner for the District of Maryland. “The government contends that St. Jude knowingly caused the submission of false claims and failed to inform the FDA with critical information about prior injuries and a death which, had the FDA been made aware, would have led to a recall. The U.S. Attorney’s Office is committed to protecting Medicare and other federal healthcare programs from fraud, and in doing so strengthen patient safety.”

The government alleges that, in late 2014, St. Jude submitted a request to the FDA to approve a change to prevent lithium clusters from draining the battery and told the FDA, “no serious injury, permanent harm or deaths have been reported associated with this” issue. However, according to the government’s allegations, St. Jude was aware at that time of two reported serious injuries and one death associated with premature battery depletion (PBD) induced by lithium clusters.

St. Jude continued to distribute devices that had been manufactured without the new design. In August 2016, St. Jude contacted the FDA and informed it that the number of PBD events had increased to 729, including two deaths and 29 events associated with loss of pacing. On Oct. 10, 2016, St. Jude issued a medical advisory regarding the PBD caused by lithium cluster shorts, which FDA classified as a Class I recall. A Class I recall is where there is a reasonable probability that violative products “will cause serious adverse health consequences, including death.” After the recall, St. Jude no longer sold the older devices, but thousands of them had been implanted into patients between Nov. 20, 2014, and Oct. 10, 2016. 

“Ensuring patient safety is our number one priority,” said Special Agent in Charge Maureen R. Dixon of the U.S. Department of Health and Human Services Office of the Inspector General (HHS-OIG). “HHS-OIG will continue to work with our law enforcement partners to investigate and hold accountable medical companies who put profits over people and ensure the integrity of the Medicare and Medicaid programs.

“The FDA regulates medical devices to assure that patient health is protected,” said Special Agent in Charge Mark S. McCormack of the FDA Office of Criminal Investigations, Metro Washington Field Office. “Reporting information untruthfully to the agency about the safety of medical devices jeopardizes patients’ health and safety. We will continue to investigate and bring to justice those who place the public health at risk.”

“The Defense Criminal Investigative Service (DCIS) and its law enforcement partners will aggressively investigate fraud that puts the health of our military members and their families at risk,” said Special Agent in Charge Christopher W. Dillard of the DCIS Mid-Atlantic Field Office. “We hope this settlement sends a clear warning to medical corporations that choose profit over patient care.”

The civil settlement includes the resolution of claims brought under the qui tam or whistleblower provisions of the False Claims Act by Debbie Burke, a patient who received one of the devices that was subject to recall. The qui tam case is captioned United States ex rel. Debbie Burke v. St. Jude Medical, Inc., No. 16-cv-3611 (D. Md.).

The resolution obtained in this matter was the result of a coordinated effort between the Civil Division’s Commercial Litigation Branch, Fraud Section; the U.S. Attorney’s Office for the District of Maryland; the Department of Health and Human Services’ Office of Inspector General and Office of General Counsel; DCIS; OPM-OIG; and the FDA’s Office of Criminal Investigations and Office of Chief Counsel.  

This matter was handled by Trial Attorney Jonathan Gold of the Civil Division and Assistant U.S. Attorneys Thomas Corcoran and Jane Andersen of the District of Maryland.

The claims resolved by the settlement are allegations only, and there has been no determination of liability, according to the Justice department press release. 

Link to the settlement agreement

Related Content to St. Jude Medical Device Battery Depletion Issue:

St. Jude Medical Recalls ICDs and CRT-D Due to Premature Battery Depletion

FDA Harshly Criticizes Abbott, St. Jude For Failure to Address EP Device Safety

Related Content

BIO-AffectDX is a multi-center, observational study that will enroll HF patients with paroxysmal, persistent and long-standing persistent AF, and a standard CRT-D indication. The study will include up to 400 participants implanted with a Biotronik Acticor CRT-DX system.

BIO-AffectDX is a multi-center, observational study that will enroll HF patients with paroxysmal, persistent and long-standing persistent AF, and a standard CRT-D indication. The study will include up to 400 participants implanted with a Biotronik Acticor CRT-DX system.

News | Cardiac Resynchronization Therapy Devices (CRT) | August 03, 2021
August 3, 2021 — In association with Heart Rhythm 2021, Biotro
News | Cardiac Resynchronization Therapy Devices (CRT) | March 03, 2021
March 3, 2021 — Medtronic announced new results from the landmark...
Left bundle branch (LBBP) activation imaging shown using wall motion color codes on echo imaging from Canon. #HRS2020 #heartrhythm2020

Left bundle branch (LBBP) activation imaging shown using wall motion color codes on dyamic echo imaging from Canon. 

News | Cardiac Resynchronization Therapy Devices (CRT) | May 13, 2020
May 13, 2020 —...
Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, Rochester, N.Y., is doing research in the BIO-LIBRA Study to determine it ICD or CRT-D devices work better in men or women with heart failure often present with non-ischemic cardiomyopathy.

Valentina Kutyifa, M.D., Ph.D., University of Rochester Medical Center, Rochester, N.Y., is doing research in the BIO-LIBRA Study to determine it ICD or CRT-D devices work better in men or women with heart failure often present with non-ischemic cardiomyopathy.

Feature | Cardiac Resynchronization Therapy Devices (CRT) | March 09, 2020 | Valentina Kutyifa M.D., Ph.D.
Cardiovascular disease is the leading cause of death for women in North America, and women with...
His Corrective Pacing Effective as an Initial Strategy for Heart Failure Cardiac Resynchronization CRT therapy vs. biventricular pacing (BiV) as a first-line strategy. #HRS #HRS19 #HRS2019
News | Cardiac Resynchronization Therapy Devices (CRT) | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in...
Biotronik Launches Acticor DX and CRT-DX Devices in U.S.
News | Cardiac Resynchronization Therapy Devices (CRT) | April 29, 2019
Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices....
Biotronik Launches Acticor and Rivacor ICD and CRT-D Devices in Europe
News | Cardiac Resynchronization Therapy Devices (CRT) | April 18, 2019
Biotronik announced the European market release of what it calls the world’s smallest implantable cardioverter...
Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...